2023-04-062024-04-052024-04-05false06938232NEW RIVER HEALTH LIMITED2024-10-03iso4217:GBPxbrli:pure069382322023-04-06069382322024-04-05069382322023-04-062024-04-05069382322022-04-06069382322023-04-05069382322022-04-062023-04-0506938232bus:SmallEntities2023-04-062024-04-0506938232bus:AuditExempt-NoAccountantsReport2023-04-062024-04-0506938232bus:AbridgedAccounts2023-04-062024-04-0506938232bus:PrivateLimitedCompanyLtd2023-04-062024-04-0506938232core:WithinOneYear2024-04-0506938232core:AfterOneYear2024-04-0506938232core:WithinOneYear2023-04-0506938232core:AfterOneYear2023-04-0506938232core:ShareCapital2024-04-0506938232core:SharePremium2024-04-0506938232core:RevaluationReserve2024-04-0506938232core:OtherReservesSubtotal2024-04-0506938232core:RetainedEarningsAccumulatedLosses2024-04-0506938232core:ShareCapital2023-04-0506938232core:SharePremium2023-04-0506938232core:RevaluationReserve2023-04-0506938232core:OtherReservesSubtotal2023-04-0506938232core:RetainedEarningsAccumulatedLosses2023-04-0506938232core:LandBuildings2024-04-0506938232core:PlantMachinery2024-04-0506938232core:Vehicles2024-04-0506938232core:FurnitureFittings2024-04-0506938232core:OfficeEquipment2024-04-0506938232core:NetGoodwill2024-04-0506938232core:IntangibleAssetsOtherThanGoodwill2024-04-0506938232core:ListedExchangeTraded2024-04-0506938232core:UnlistedNon-exchangeTraded2024-04-0506938232core:LandBuildings2023-04-0506938232core:PlantMachinery2023-04-0506938232core:Vehicles2023-04-0506938232core:FurnitureFittings2023-04-0506938232core:OfficeEquipment2023-04-0506938232core:NetGoodwill2023-04-0506938232core:IntangibleAssetsOtherThanGoodwill2023-04-0506938232core:ListedExchangeTraded2023-04-0506938232core:UnlistedNon-exchangeTraded2023-04-0506938232core:LandBuildings2023-04-062024-04-0506938232core:PlantMachinery2023-04-062024-04-0506938232core:Vehicles2023-04-062024-04-0506938232core:FurnitureFittings2023-04-062024-04-0506938232core:OfficeEquipment2023-04-062024-04-0506938232core:NetGoodwill2023-04-062024-04-0506938232core:IntangibleAssetsOtherThanGoodwill2023-04-062024-04-0506938232core:ListedExchangeTraded2023-04-062024-04-0506938232core:UnlistedNon-exchangeTraded2023-04-062024-04-0506938232core:MoreThanFiveYears2023-04-062024-04-0506938232core:Non-currentFinancialInstruments2024-04-0506938232core:Non-currentFinancialInstruments2023-04-0506938232dpl:CostSales2023-04-062024-04-0506938232dpl:DistributionCosts2023-04-062024-04-0506938232core:LandBuildings2023-04-062024-04-0506938232core:PlantMachinery2023-04-062024-04-0506938232core:Vehicles2023-04-062024-04-0506938232core:FurnitureFittings2023-04-062024-04-0506938232core:OfficeEquipment2023-04-062024-04-0506938232dpl:AdministrativeExpenses2023-04-062024-04-0506938232core:NetGoodwill2023-04-062024-04-0506938232core:IntangibleAssetsOtherThanGoodwill2023-04-062024-04-0506938232dpl:GroupUndertakings2023-04-062024-04-0506938232dpl:ParticipatingInterests2023-04-062024-04-0506938232dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-062024-04-0506938232core:ListedExchangeTraded2023-04-062024-04-0506938232dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-062024-04-0506938232core:UnlistedNon-exchangeTraded2023-04-062024-04-0506938232dpl:CostSales2022-04-062023-04-0506938232dpl:DistributionCosts2022-04-062023-04-0506938232core:LandBuildings2022-04-062023-04-0506938232core:PlantMachinery2022-04-062023-04-0506938232core:Vehicles2022-04-062023-04-0506938232core:FurnitureFittings2022-04-062023-04-0506938232core:OfficeEquipment2022-04-062023-04-0506938232dpl:AdministrativeExpenses2022-04-062023-04-0506938232core:NetGoodwill2022-04-062023-04-0506938232core:IntangibleAssetsOtherThanGoodwill2022-04-062023-04-0506938232dpl:GroupUndertakings2022-04-062023-04-0506938232dpl:ParticipatingInterests2022-04-062023-04-0506938232dpl:GroupUndertakingscore:ListedExchangeTraded2022-04-062023-04-0506938232core:ListedExchangeTraded2022-04-062023-04-0506938232dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-04-062023-04-0506938232core:UnlistedNon-exchangeTraded2022-04-062023-04-0506938232core:NetGoodwill2024-04-0506938232core:IntangibleAssetsOtherThanGoodwill2024-04-0506938232core:LandBuildings2024-04-0506938232core:PlantMachinery2024-04-0506938232core:Vehicles2024-04-0506938232core:FurnitureFittings2024-04-0506938232core:OfficeEquipment2024-04-0506938232core:AfterOneYear2024-04-0506938232core:WithinOneYear2024-04-0506938232core:ListedExchangeTraded2024-04-0506938232core:UnlistedNon-exchangeTraded2024-04-0506938232core:ShareCapital2024-04-0506938232core:SharePremium2024-04-0506938232core:RevaluationReserve2024-04-0506938232core:OtherReservesSubtotal2024-04-0506938232core:RetainedEarningsAccumulatedLosses2024-04-0506938232core:NetGoodwill2023-04-0506938232core:IntangibleAssetsOtherThanGoodwill2023-04-0506938232core:LandBuildings2023-04-0506938232core:PlantMachinery2023-04-0506938232core:Vehicles2023-04-0506938232core:FurnitureFittings2023-04-0506938232core:OfficeEquipment2023-04-0506938232core:AfterOneYear2023-04-0506938232core:WithinOneYear2023-04-0506938232core:ListedExchangeTraded2023-04-0506938232core:UnlistedNon-exchangeTraded2023-04-0506938232core:ShareCapital2023-04-0506938232core:SharePremium2023-04-0506938232core:RevaluationReserve2023-04-0506938232core:OtherReservesSubtotal2023-04-0506938232core:RetainedEarningsAccumulatedLosses2023-04-0506938232core:NetGoodwill2022-04-0606938232core:IntangibleAssetsOtherThanGoodwill2022-04-0606938232core:LandBuildings2022-04-0606938232core:PlantMachinery2022-04-0606938232core:Vehicles2022-04-0606938232core:FurnitureFittings2022-04-0606938232core:OfficeEquipment2022-04-0606938232core:AfterOneYear2022-04-0606938232core:WithinOneYear2022-04-0606938232core:ListedExchangeTraded2022-04-0606938232core:UnlistedNon-exchangeTraded2022-04-0606938232core:ShareCapital2022-04-0606938232core:SharePremium2022-04-0606938232core:RevaluationReserve2022-04-0606938232core:OtherReservesSubtotal2022-04-0606938232core:RetainedEarningsAccumulatedLosses2022-04-0606938232core:AfterOneYear2023-04-062024-04-0506938232core:WithinOneYear2023-04-062024-04-0506938232core:Non-currentFinancialInstrumentscore:CostValuation2023-04-062024-04-0506938232core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-04-062024-04-0506938232core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-04-062024-04-0506938232core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-04-062024-04-0506938232core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-04-062024-04-0506938232core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-04-062024-04-0506938232core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-04-062024-04-0506938232core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-04-062024-04-0506938232core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-04-062024-04-0506938232core:Non-currentFinancialInstrumentscore:CostValuation2024-04-0506938232core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-04-0506938232core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-04-0506938232core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-04-0506938232core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-04-0506938232core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-04-0506938232core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-04-0506938232core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-04-0506938232core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-04-0506938232core:Non-currentFinancialInstrumentscore:CostValuation2023-04-0506938232core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-04-0506938232core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-04-0506938232core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-04-0506938232core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-04-0506938232core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-04-0506938232core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-04-0506938232core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-04-0506938232core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-04-0506938232bus:Director12023-04-062024-04-0506938232bus:Director22023-04-062024-04-0506938232bus:Director32023-04-062024-04-0506938232bus:Director42023-04-062024-04-0506938232bus:Director52023-04-062024-04-05

NEW RIVER HEALTH LIMITED

Registered Number
06938232
(England and Wales)

Unaudited Financial Statements for the Year ended
5 April 2024

NEW RIVER HEALTH LIMITED
Company Information
for the year from 6 April 2023 to 5 April 2024

Directors

FLETCHER, Ian Harris, Dr
NOLAN WORNELL, Frances, Dr
NOOR, Rizwana, Dr
PATEL, Sanjay, Dr
STERN, Glenn, Dr

Company Secretary

PATEL, Sanjay, Dr

Registered Address

Ramsay Brown Llp The Brentano Suite
Solar House, 915 High Road
North Finchley
N12 8QJ

Registered Number

06938232 (England and Wales)
NEW RIVER HEALTH LIMITED
Balance Sheet as at
5 April 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Intangible assets349,99766,664
Tangible assets419,58022,489
69,57789,153
Current assets
Stocks134,197127,411
Debtors5361,666585,445
Cash at bank and on hand890,619418,161
1,386,4821,131,017
Creditors amounts falling due within one year6(259,107)(364,294)
Net current assets (liabilities)1,127,375766,723
Total assets less current liabilities1,196,952855,876
Net assets1,196,952855,876
Capital and reserves
Called up share capital8,5008,500
Profit and loss account1,188,452847,376
Shareholders' funds1,196,952855,876
The financial statements were approved and authorised for issue by the Board of Directors on 3 October 2024, and are signed on its behalf by:
PATEL, Sanjay, Dr
Director
Registered Company No. 06938232
NEW RIVER HEALTH LIMITED
Notes to the Financial Statements
for the year ended 5 April 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes.
Operating leases
Where, substantially, all the risks and rewards of ownership of the asset do not transfer from the lessor to the company, the lease is treated as an operating lease. Rentals payable under operating leases are charged to the profit and loss account on a straight-line basis over the period of the lease.
Defined contribution pension plan
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Intangible assets
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation. Patents Lloyds Pharmacy License is stated at cost less accumulated depreciation and any accumulated impairment losses. It is amortised on a straightline method at 6.66%. If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new expectations.
Tangible fixed assets and depreciation
Property, plant and equipment is stated at cost less accumulated depreciation and impairment losses. Part of an item of property, plant and equipment having different useful lives are accounted for as separate items. Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives, using the straightline method. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis. Depreciation is provided to write off the cost less estimated residual value, of each asset over its expected useful life as follows:

Reducing balance (%)Straight line (years)
Fixtures and fittings15-
Office Equipment-25
Stocks and work in progress
Stocks are measured at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.
2.Average number of employees

20242023
Average number of employees during the year115
3.Intangible assets

Total

£
Cost or valuation
At 06 April 23250,000
At 05 April 24250,000
Amortisation and impairment
At 06 April 23183,336
Charge for year16,667
At 05 April 24200,003
Net book value
At 05 April 2449,997
At 05 April 2366,664
4.Tangible fixed assets

Total

£
Cost or valuation
At 06 April 23196,829
Additions618
At 05 April 24197,448
Depreciation and impairment
At 06 April 23174,339
Charge for year3,528
At 05 April 24177,867
Net book value
At 05 April 2419,580
At 05 April 2322,489
5.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables169,460323,644
Other debtors183,706253,301
Called up share capital not paid, current asset8,5008,500
Total361,666585,445
6.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables139,990284,859
Bank borrowings and overdrafts-6,260
Taxation and social security116,21070,449
Accrued liabilities and deferred income2,9072,726
Total259,107364,294
7.Directors advances, credits and guarantees
At the year end, the company owed £0 (2023: £6,260) to the director.
8.Related party transactions
As at the year end, the company was owed by Green Lanes Medical LLP £125,000 (2023: £175,000), a partnership in which the directors of the company are members. Interest is chargeable at 3.1% per annum.
9.Controlling party
The company was controlled throughout the year by its directors.